WHIPPANY, N.J., Feb. 5, 2015 /PRNewswire/ --
"During her nearly six years of leadership at the U.S. Food and Drug Administration, Commissioner Margaret Hamburg has been deeply committed to public health, while working hard to foster an environment for growth in science and innovation throughout the pharmaceutical and medical device industries. FDA has also evolved in the way it engages with industry, which has improved the drug development process and other interactions with the agency. During her tenure, Bayer has been able to introduce seven FDA approved new molecular entities to meet the needs of patients, including those who suffer from rare diseases. On behalf of Bayer and the patients we serve, I congratulate Commissioner Hamburg on a job well done and the strong legacy she leaves behind. We look forward to continuing our work with the new leadership and the rest of the FDA team."
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/statement-from-phillip-blake-president-of-bayer-corporation-on-fda-commissioner-margaret-hamburg-md-300031954.html
SOURCE Bayer Corporation